Here is a thorough overview of the Hepatitis A (HepA) vaccine:
Hepatitis A Vaccine
The Virus and Transmission
Hepatitis A virus (HAV) spreads primarily by the fecal-oral route - person-to-person contact or ingestion of contaminated food and water. Rarely, it can be transmitted by blood products.
Available Vaccines
Three commercially available inactivated (killed virus) vaccines are licensed in the United States:
| Vaccine | Type | Ages |
|---|
| Havrix | Single-antigen HAV | ≥1 year |
| Vaqta | Single-antigen HAV | ≥1 year |
| Twinrix | Combined HepA + HepB | ≥18 years (adults) |
All are given intramuscularly (IM). Each formulation has different dosing volumes, so the package insert should be consulted for exact doses.
Schedule
- Standard 2-dose series: 0 and 6-18 months apart
- Twinrix (Hep A+B combo): 0, 1, and 6 months; or an accelerated schedule of 0, 1, 3 weeks + 12 months
- After the full 2-dose series, no booster doses are required
For travelers, a single dose provides protection beginning approximately 4 weeks after injection. The combination with immune globulin (IG) is reserved for specific high-risk or immunocompromised situations.
Efficacy and Duration
- 94-100% of recipients develop protective antibody levels 1 month after a single dose
- Havrix: ~94% efficacy after 2 doses in RCT; Vaqta: ~100% efficacy after 1 dose in placebo-controlled trial
- Protective anti-HAV levels persist in >97% of subjects 15-17 years after primary vaccination
- Mathematical modeling suggests likely lifelong protection - boosters are not needed
- In the post-exposure setting, hepatitis A vaccine is as effective as immune globulin for preventing symptomatic HAV infection
Who Should Be Vaccinated (Indications)
Routine:
- All children aged 12-23 months (universal childhood vaccination)
- Catch-up for unimmunized children/adolescents ages 2-18
- All adults who want immunity
Risk-based:
- Travelers to or residents of HAV-endemic countries (high/intermediate endemicity)
- Close contacts of internationally adopted children (within 60 days of arrival)
- Men who have sex with men (MSM)
- Injection and non-injection drug users
- Persons experiencing homelessness (age >1 year)
- Persons with chronic liver disease (including hepatitis B, hepatitis C, MASLD/NAFLD)
- Persons with HIV infection
- Persons with clotting factor disorders
- Laboratory workers handling HAV or fecal specimens
- Primate handlers
- Pregnant women at risk of infection or severe outcomes
- Military personnel
Post-Exposure Prophylaxis (PEP)
As of updated 2020 ACIP guidance:
- Hepatitis A vaccine (not IG) is now the preferred PEP for persons aged ≥12 months, given within 14 days of last exposure
- IG (0.1 mL/kg IM) is retained for:
- Infants aged <12 months
- Persons with contraindications to the vaccine
- Immunocompromised adults and those with chronic liver disease (give both vaccine + IG at different IM sites)
- For infants <6 months traveling to endemic areas: IG at 0.1 mL/kg (≤1 month), 0.2 mL/kg (up to 2 months), then repeat 0.2 mL/kg every 2 months
Special Populations
- Pregnancy: Vaccine is inactivated, so risk to fetus is expected to be low; can be given to pregnant women at risk
- Immunocompromised / HIV: Safe to administer, but antibody response may be reduced - particularly in HIV-positive persons with low CD4 counts (response rates 47-88%)
- Chronic liver disease: Safe and effective; vaccination is specifically recommended
- IgA deficiency: Avoid IG due to anaphylaxis risk
Safety
The vaccine is well tolerated. Serious adverse events (Guillain-Barre syndrome, anaphylaxis, transverse myelitis, erythema multiforme) have been reported but are rare across millions of doses administered.
- Can be co-administered with hepatitis B vaccine without affecting immunogenicity of either
- Does not interfere with inactivated vaccines; avoid giving live attenuated vaccines within 2 weeks of IG (not the HepA vaccine itself)
- Pre- or post-vaccination serological testing is not recommended (adds cost, vaccination poses no risk even if already immune)
Sources: Harrison's Principles of Internal Medicine 22E (2025); Yamada's Textbook of Gastroenterology, 7th ed.; Textbook of Family Medicine, 9e; Goldman-Cecil Medicine; 2025-2026 CDC/AAP Immunization Schedule